Skip to main content
. Author manuscript; available in PMC: 2020 Aug 8.
Published in final edited form as: Bioconjug Chem. 2019 Sep 13;31(1):28–36. doi: 10.1021/acs.bioconjchem.9b00546

Figure 3.

Figure 3.

Active irinotecan derivative SN-38 coupled to a MAb with a cleavable linker at the heterocycle’s 20 ring oxygen position designed to produce the free active drug upon bond cleavage. The remaining linker consists of a solubilizing 7-PEG unit to counter the free drugs inherent hydrophobicity leading to a maleimide used for coupling to MAb cysteinyl- thiol groups.